PRODUCT INFORMATION

CLARITHROMYCIN SANDOZ 250MG AND 500MG TABLETS

NAME OF THE MEDICINE

Generic name: Clarithromycin.


Other names 6-O-methylerythromycin A

Chemical structure:

\[
\text{CAS number 81103-11-9} 
\quad \text{C}_{38}\text{H}_{69}\text{NO}_{13} 
\quad \text{MW:747.95 g/mol}
\]

DESCRIPTION

Clarithromycin is a white to off-white crystalline powder. It is soluble in acetone, slightly soluble in methanol, ethanol and acetonitrile and practically insoluble in water.

In addition to clarithromycin, Clarithromycin Sandoz tablets contain: cellulose-microcrystalline, magnesium stearate, croscarmellose sodium, cellulose-powdered, silica-colloidal anhydrous, lactose monohydrate, hypromellose, macrogol 4000 and titanium dioxide.

PHARMACOLOGY

Clarithromycin is a semi-synthetic macrolide antibiotic.
Hepatotoxicity, atrophy of lymphatic tissues (lymph, thymus) and adverse reproductive toxicity were seen in several species at exposures less than those which might be expected clinically at proposed doses. The clinical significance of these observations is not known. There are no data from long term animal carcinogenicity studies.

**Clinical Pharmacology**

*Helicobacter pylori* is strongly associated with peptic ulcer disease. Ninety to 100% of patients with peptic ulcers are infected with this pathogen. Eradication of *H. pylori* is associated with a reduction in the rate of duodenal ulcer recurrence, thereby reducing the need for maintenance anti-secretory therapy.

The development of antimicrobial resistance may have an adverse effect on eradication regimens. The clinical impact of clarithromycin resistance on *H. pylori* eradication has not been studied.

The optimal treatment regimen for the eradication of *H. pylori* is yet to be determined.

**Pharmacokinetics**

Clarithromycin is absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability of 250mg tablets is approximately 50%. Two 250mg tablets have been shown to be bioequivalent to one 500mg tablet. In a study, the mean $C_{\text{max}}$ and AUC values after a single oral dose of 500mg clarithromycin (fasting state) was $2.37 \pm 0.63 \ \mu\text{g/mL}$ and $16.9 \pm 4.44 \ \mu\text{g.h/mL}$ respectively.

In studies of fasting healthy adults, peak serum concentrations were attained within 1.8 hours after oral dosing. Steady-state peak serum clarithromycin concentrations were attained in two to three days and were approximately 1 microgram/mL with a 250 mg dose administered every 12 hours and 2 to 3 microgram/mL with a 500 mg dose administered every 12 hours. The elimination half-life of clarithromycin was about three to four hours with 250 mg administered every 12 hours but increased to five to seven hours with 500 mg administered every 12 hours. The nonlinearity of clarithromycin pharmacokinetics is slight at the recommended doses of 250 and 500 mg administered every 12 hours but is quite marked at higher doses. With a dosing of 250 mg every 12 hours, the principal metabolite, 14-OH clarithromycin, attains a peak steady-state concentration of about 0.6 microgram/mL and has an elimination half-life of five to six hours. With a dosing of 500 mg every 12 hours, the peak steady-state concentration of 14-OH clarithromycin is slightly higher (up to 1 microgram/mL) and its elimination half-life is about seven hours. With either dose, the steady-state concentration of this metabolite is generally attained within two to three days.

Clarithromycin and the 14-OH clarithromycin metabolite distribute readily into body tissues and fluids. *In vitro* studies showed that protein binding of clarithromycin in human plasma averaged about 70% at clinically-relevant concentrations of 0.45 to 4.5 mg/mL. Because of high
intracellular concentrations, tissue concentrations may be higher than serum concentrations (see table). Animal studies indicate that clarithromycin penetration into the CNS is poor.

<table>
<thead>
<tr>
<th>Tissue Type</th>
<th>Tissue (µg/g)</th>
<th>Serum (µg/mL)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tonsil</td>
<td>1.6</td>
<td>0.8</td>
</tr>
<tr>
<td>Lung</td>
<td>8.8</td>
<td>1.7</td>
</tr>
</tbody>
</table>

Information was obtained regarding the penetration of clarithromycin in middle ear fluid in paediatric patients with otitis media. Approximately 2.5 hours after receiving the fifth dose (dosage was 7.5 mg/kg twice a day) the mean concentration of clarithromycin was 2.53 µg/g fluid in the middle ear and for the 14-OH metabolite was 1.27 µg/g. The concentrations of parent drug and 14-OH metabolite were variable, with two thirds of patients having levels greater than corresponding concentration in serum and one third of patients having levels similar or lower. The mean ratio was 2.48 ± 3.57.

Approximately 20% of a 250 mg oral dose given every 12 hours is excreted in the urine as unchanged clarithromycin. After a dose of 500 mg every 12 hours, urinary excretion of unchanged parent drug is approximately 30%. The renal clearance of clarithromycin is however, relatively independent of the dose size and approximates the normal glomerular filtration rate. The major metabolite found in urine is 14-OH-clarithromycin which accounts for an additional 10% to 15% of either a 250 mg or 500 mg dose administered every 12 hours.

A number of drugs are metabolised by specific forms (isoforms) of the cytochrome-P450 enzyme system. If two drugs are metabolised by the same isoform, the propensity for an interaction between the two drugs is magnified.

Studies demonstrate that clarithromycin undergoes cytochrome-P450 dependent N-demethylation and 14-(R)-hydroxylation in the presence of human liver microsomes. Available data indicate that N-demethylation and 14-(R)-hydroxylation of clarithromycin are mediated principally by members of the CYP3A subfamily, most likely CYP3A4, and that CYP2C19, CYP2D6, CYP2E1, CYP1A2, CYP2C9 and CYP2A6 play relatively minor roles.

**Impaired Hepatic Function:** The steady-state concentrations of clarithromycin in patients with impaired hepatic function did not differ from those of normal patients; however, the 14-OH-clarithromycin concentrations were lower in the hepatically impaired patients. The decreased formation of 14-OH-clarithromycin was at least partially offset by an increase in renal clearance of clarithromycin in the patients with impaired hepatic function when compared to healthy patients.
Impaired Renal Function: The pharmacokinetics of clarithromycin were also altered in patients with impaired renal function who received multiple 500 mg doses. The plasma levels, half life, C<sub>max</sub>, C<sub>min</sub> for both clarithromycin and its 14-OH metabolite were higher and the AUC was larger in patients with renal impairment than in normal patients. The extent to which these parameters differed was correlated with the degree of renal impairment; the more severe the renal impairment, the more significant the difference. Plasma levels and elimination half-life start increasing at creatinine clearance values of less than 30 mL/min. The need for dosage adjustment should be considered in such cases. (see DOSAGE AND ADMINISTRATION).

Helicobacter pylori infection with concomitant omeprazole administration: A pharmacokinetic study was conducted with clarithromycin 500 mg three times a day and omeprazole 40 mg daily. When clarithromycin was given alone at 500 mg every eight hours, the mean steady-state C<sub>max</sub> value was approximately 3.8 µg/mL and the mean C<sub>min</sub> value was approximately 1.8 µg/mL. The mean AUC<sub>0-8</sub> for clarithromycin was 22.9 µg·hr/mL. The T<sub>max</sub> and half-life were 2.1hr and 5.3hr, respectively, when clarithromycin was dosed at 500 mg three times a day.

In the same study when clarithromycin 500 mg three times a day was administered with omeprazole 40 mg daily, increases in omeprazole half-life and AUC<sub>0-24</sub> were observed. For all subjects combined, the mean omeprazole AUC<sub>0-24</sub> was 89% greater and the harmonic mean for omeprazole T<sub>1/2</sub> was 34% greater when omeprazole was administered with clarithromycin than when omeprazole was administered alone. When clarithromycin was administered with omeprazole, the steady state C<sub>max</sub>, C<sub>min</sub>, and AUC<sub>0-8</sub> of clarithromycin were increased by 10%, 27%, and 15%, respectively, over values achieved when clarithromycin was administered with placebo.

At steady state, clarithromycin gastric mucus concentrations 6 hours post-dosing were approximately 25-fold higher in the clarithromycin - omeprazole group compared with the Clarithromycin alone group. Six hours post-dosing, mean clarithromycin gastric tissue concentrations were approximately 2-fold higher when clarithromycin was given with omeprazole than when clarithromycin was given with placebo.

Mycobacterial infection: The steady-state concentrations of clarithromycin and 14-OH-clarithromycin in adults with HIV infection did not differ from those in non HIV infected patients. However, at the higher doses which may be required to treat mycobacterial infections, clarithromycin concentrations were much higher than those observed at the usual doses.

In adult HIV infected patients taking 1000 mg/day in two divided doses, steady state clarithromycin C<sub>max</sub> values ranged from 5 to 10 µg/mL. Elimination half-lives appeared to be lengthened at these higher doses as compared to that seen with usual doses in non HIV infected patients. The higher plasma concentrations and longer elimination half lives observed at these doses are consistent with the known non linearity of clarithromycin pharmacokinetics.
Microbiology

Clarithromycin exerts its antibacterial action by binding to the 50S ribosomal subunits of susceptible organisms and inhibiting protein synthesis. The minimum inhibitory concentrations (MIC) of clarithromycin are generally one log₂ dilution more potent than the MICs of erythromycin. However, clarithromycin is much more potent than erythromycin against atypical mycobacteria.

Clarithromycin is active in vitro and in vivo against the organisms listed below:

<table>
<thead>
<tr>
<th>USUALLY SENSITIVE BACTERIA</th>
<th>NON-SENSITIVE BACTERIA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chlamydia pneumoniae</td>
<td>Enterobacteriaceae</td>
</tr>
<tr>
<td>Haemophilus influenzae</td>
<td>Pseudomonas species</td>
</tr>
<tr>
<td>Haemophilus parainfluenzae</td>
<td></td>
</tr>
<tr>
<td>Helicobacter pylori</td>
<td></td>
</tr>
<tr>
<td>Legionella pneumophila</td>
<td></td>
</tr>
<tr>
<td>Moraxella Branhamella</td>
<td></td>
</tr>
<tr>
<td>Mycobacterium avium</td>
<td></td>
</tr>
<tr>
<td>Mycobacterium chelonae</td>
<td></td>
</tr>
<tr>
<td>Mycobacterium intracellulare</td>
<td></td>
</tr>
<tr>
<td>Mycoplasma pneumoniae</td>
<td></td>
</tr>
<tr>
<td>Staphylococcus aureus</td>
<td></td>
</tr>
<tr>
<td>Streptococcus pneumoniae</td>
<td></td>
</tr>
<tr>
<td>Streptococcus pyogenes</td>
<td></td>
</tr>
<tr>
<td>α- haemolytic Streptococci (viridans group)</td>
<td></td>
</tr>
</tbody>
</table>

Note:
1. Most strains of methicillin-resistant and oxacillin-resistant staphylococci are resistant to clarithromycin.
2. Clarithromycin is not active in vitro against M. tuberculosis.

The principal metabolite of clarithromycin in man is a microbiologically active metabolite, 14-OH-clarithromycin. This metabolite is as active or one to two fold less active than the parent compound for most organisms, except against H influenzae where it is twice as active.

Clarithromycin was found to be 2 to 10 times more active than erythromycin in several experimental animal infection models. It was shown, for example, to be more effective than erythromycin in mouse systemic infection, mouse subcutaneous abscess and mouse respiratory tract infections caused by S. pneumoniae, S. aureus, S. pyogenes and H. influenzae. In guinea pigs with Legionella infection, this effect is more pronounced; an intraperitoneal dose of 1.6 mg/kg/day of clarithromycin was more effective than 50 mg/kg/day of erythromycin.
**Susceptibility Testing of Bacteria Other Than Atypical Mycobacteria:**

Dilution or diffusion techniques – either quantitative (MIC) or breakpoint, should be used following a regularly updated, recognised and standardised method (e.g. NCCLS). Standardised susceptibility test procedures require the use of laboratory control microorganisms to control the technical aspects of the laboratory procedures.

A report of “Susceptible” indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of “Intermediate” indicates that the result should be considered equivocal, and if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone, which prevents small-uncontrolled technical factors from causing major discrepancies in interpretation. A report of “Resistant” indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.

Note: The prevalence of resistance may vary geographically for selected species and local information on resistance is desirable, particularly when treating severe infections.

**Susceptibility Testing of Atypical Mycobacteria:** No standard reference method for susceptibility testing of atypical mycobacteria currently exists, nor has a correlation between the results of *in vitro* susceptibility testing and clinical efficacy been clearly established. Clinical isolates of *M. avium* and *M. intracellulare* resistant to clarithromycin have been reported. Susceptibility testing of atypical mycobacteria requires specialised techniques and media, and should be referred to a mycobacterial reference laboratory.

**CLINICAL TRIALS**

In a well controlled, double blind study, *H. pylori* infected duodenal ulcer patients received triple therapy with clarithromycin 500 mg bid, amoxycillin 1000 mg bid and omeprazole 20 mg daily for 10 days or dual therapy with clarithromycin 500 mg tid and omeprazole 40 mg daily for 14 days. *H. pylori* was eradicated in 88% of the patients (intent-to-treat analysis) receiving triple therapy and in 55% of the patients (intent-to-treat analysis) receiving dual therapy.

In well controlled, double blind studies, *H. pylori* infected duodenal ulcer patients received eradication therapy with clarithromycin 500 mg tid and omeperazole 40mg daily for 14 days, followed by omeprazole 40 mg (study A) or omeprazole 20 mg (study B, C, D) daily for an additional 14 days. Patients in each control group received omeprazole alone for 28 days. In study A, *H. pylori* was eradicated in 81% of patients (intent-to-treat analysis), who received clarithromycin and omeprazole and in only 1% in patients receiving omeprazole alone. In studies B, C, and D, the combined eradication rate was from 56 to 68% (intent-to-treat analysis), in patients receiving clarithromycin and omeprazole and less than 1% in patients receiving...
omeprazole alone. The rate of ulcer recurrence at 6 months was statistically lower in the clarithromycin and omeprazole treated patients when compared to patients receiving omeprazole alone.

The development of antimicrobial resistance may have an adverse effect on eradication regimens. The clinical impact of clarithromycin resistance on *H. pylori* eradication has not been studied.

The optimal treatment regimen for the eradication of *H. pylori* is yet to be determined.

In a randomised, double-blind study of the safety and efficacy of clarithromycin for the prevention of disseminated *Mycobacterium avium* Complex (MAC) infection in HIV-infected patients with CD4 counts \( \leq 100 \) cells/mm\(^3\), 113 (33.9%) clarithromycin patients and 155 (46.4%) placebo patients either died or developed a MAC infection. This represents a statistically significant (\( p < 0.001 \)) reduction of 37% in the combined risk of developing MAC or dying for the clarithromycin group compared to the placebo group. The following figure summarises the analysis of MAC-free survival:

<table>
<thead>
<tr>
<th></th>
<th>Clarithromycin (n=333)</th>
<th>Placebo (n=334)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Events</td>
<td>113 (33.9%)</td>
<td>155 (46.4%)</td>
</tr>
<tr>
<td>Quartiles</td>
<td></td>
<td></td>
</tr>
<tr>
<td>25(^{th})</td>
<td>356 days</td>
<td>250 days</td>
</tr>
<tr>
<td>Median</td>
<td>582 days</td>
<td>473 days</td>
</tr>
<tr>
<td>75(^{th})</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Hazard ratio</td>
<td>0.627 ( p &lt; 0.001*** )</td>
<td></td>
</tr>
</tbody>
</table>
INDICATIONS

Clarithromycin Sandoz (clarithromycin) is indicated for use in adults and children older than 12 years for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below:

1. Acute streptococcal pharyngitis

2. Community acquired pneumonia due to *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, *Legionella pneumophila* and *Streptococcus pneumoniae*

3. Uncomplicated skin and skin structure infections due to *Staphylococcus aureus* or *Streptococcus pyogenes*

4. Disseminated or localised mycobacterial infections due to *Mycobacterium avium* or *Mycobacterium intracellulare* and skin and skin structure infections due to *Mycobacterium chelonae*. Clarithromycin should be used in combination with other antimycobacterial agents

5. Prevention of disseminated *Mycobacterium avium* complex infection in HIV-infected adults with CD4 lymphocyte counts <75 cells/mm$^3$ (see PRECAUTIONS). Disseminated infection due to *Mycobacterium avium* complex should be excluded by a negative blood culture prior to commencement of prophylaxis

6. Acute bacterial exacerbation of chronic bronchitis due to *Haemophilus influenzae*, *Moraxella catarrhalis* or *Streptococcus pneumoniae*

7. Combination therapy for the treatment of peptic ulcer disease associated with *Helicobacter pylori* infection

Clarithromycin Sandoz (clarithromycin) is indicated for use in children for the treatment of mild to moderately severe infections caused by susceptible strains of the designated micro-organisms in the conditions listed below:

1. Acute streptococcal pharyngitis and tonsillitis caused by *Streptococcus pyogenes*

2. Community acquired pneumonia including infections due to *Chlamydia pneumoniae*, *Mycoplasma pneumoniae* and *Legionella pneumophila*

3. Skin and skin structure infections (eg impetigo)

4. Disseminated or localised infections due to *Mycobacterium avium* or *Mycobacterium intracellulare* in immunocompromised children, including those with HIV Infection or AIDS

5. Acute otitis media
NOTE:

1. Penicillins are the drug of first choice in the treatment of acute otitis media.

2. Penicillin is the usual drug of choice in the treatment and prevention of streptococcal infections including prophylaxis of rheumatic fever. Clarithromycin appears to be as effective as phenoxymethylpenicillin in the eradication of streptococci from the nasopharynx, however substantial data establishing the efficacy of clarithromycin in the subsequent prevention of rheumatic fever are not available at present.

3. There is insufficient evidence of efficacy to support the use of Clarithromycin Sandoz in acute bronchitis in young children.

4. The data presented on infections of skin and skin structure were confined largely to mild to moderate infections such as impetigo.

CONTRAINDICATIONS

Clarithromycin is contraindicated in patients with known hypersensitivity to macrolide antibiotic drugs or any of its excipients.

Clarithromycin is contraindicated as concurrent therapy with astemizole, cisapride, pimozide, terfenadine, as this may result in QT prolongation and cardiac arrhythmias, including ventricular tachycardia, ventricular fibrillation, and torsades de pointes (see INTERACTIONS WITH OTHER MEDICINES).

Concomitant administration of clarithromycin and ergot alkaloids (e.g. ergotamine or dihydroergotamine is contraindicated, as this may result in ergot toxicity (see PRECAUTIONS, INTERACTIONS WITH OTHER MEDICINES).

Concomitant administration of clarithromycin and oral midazolam is contraindicated (see INTERACTIONS WITH OTHER MEDICINES).

Clarithromycin should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes (see PRECAUTIONS, INTERACTIONS WITH OTHER MEDICINES).

Clarithromycin should not be given to patients with hypokalaemia (risk of prolongation of QT-time).

Clarithromycin should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolised by CYP3A4 (lovastatin or simvastatin) due to the risk of myopathy, including rhabdomyolysis. Treatment with these agents should be discontinued during clarithromycin treatment (see PRECAUTIONS).
Clarithromycin (and other strong CYP3A4 inhibitors) should not be used concomitantly with colchicine (see PRECAUTIONS and INTERACTIONS WITH OTHER MEDICINES). Concomitant administration with ticagrelor or ranolazine is contraindicated.

Clarithromycin should not be used in patients who suffer from severe hepatic failure in combination with renal impairment.

**PRECAUTIONS**

The physician should not prescribe clarithromycin to pregnant women without carefully weighing the benefits against risk, particularly during the first three months of pregnancy (see Use In Pregnancy).

Caution is advised in patients with severe renal insufficiency (see DOSAGE AND ADMINISTRATION).

Use with caution in the following circumstances:

Clarithromycin is principally excreted via the liver and kidney. Clarithromycin may be administered without dosage adjustment to patients with hepatic impairment and normal renal function. However, in the presence of significant renal impairment with or without coexisting hepatic impairment, decreased dosage or prolonged dosing intervals may be appropriate (see DOSAGE AND ADMINISTRATION).

*In vitro* studies have demonstrated cross-resistance between clarithromycin, erythromycin, azithromycin and other macrolides, as well as lincomycin and clindamycin. Attention should be paid to this possibility when considering the use of clarithromycin.

Use of any antimicrobial therapy, such as clarithromycin, to treat *H. pylori* infection may select for drug-resistant organisms. Long-term use may, as with other antibiotics, result in colonisation with increased numbers of non-susceptible bacteria and fungi. If superinfections occur, appropriate therapy should be instituted.

Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with clarithromycin. This hepatic dysfunction may be severe and is usually reversible. Cases of fatal hepatic failure (see ADVERSE EFFECTS) have been reported. Some patients may have had pre-existing hepatic disease or may have been taking other hepatotoxic medicinal products. Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop, such as anorexia, jaundice, dark urine, pruritus, or tender abdomen.
Pseudomembranous colitis

Antibiotic associated pseudomembranous colitis has been reported with many antibiotics including macrolides and may range in severity from mild to life-threatening. A toxin produced by *Clostridium difficile* appears to be the primary cause. The severity of the colitis may range from mild to life threatening. *Clostridium difficile*-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents including clarithromycin, and may range in severity from mild diarrhea to fatal colitis. Treatment with antibacterial agents alters the normal flora of the colon, which may lead to overgrowth of *C. difficile*. CDAD must be considered in all patients who present with diarrhea following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. Therefore, discontinuation of clarithromycin therapy should be considered regardless of the indication.

It is important to consider this diagnosis in patients who develop diarrhoea or colitis in association with antibiotic use (this may occur up to several weeks after cessation of antibiotic therapy). Mild cases usually respond to drug discontinuation alone. However, in moderate to severe cases appropriate therapy with a suitable oral antibacterial agent effective against *C. difficile* should be considered. Fluids, electrolytes and protein replacement should be provided when indicated. Drugs which delay peristalsis, e.g. opiates and diphenoxylate with atropine (Lomotil), may prolong and/or worsen the condition and should not be used.

Microbial testing should be performed and adequate treatment initiated. Drugs inhibiting peristalsis should be avoided.

**Myasthenia Gravis**

Exacerbation of symptoms of myasthenia gravis has been reported in patients receiving clarithromycin therapy.

**Colchicine**

There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency. Deaths have been reported in some such patients. Concomitant administration of clarithromycin and colchicine is contraindicated (see CONTRAINDICATIONS).

**Triazolobenzodiazepines**

Caution is advised regarding concomitant administration of clarithromycin and triazolobenzodiazepines, such as triazolam, and midazolam (see INTERACTIONS WITH OTHER MEDICINES).
Ototoxic Drugs
Caution is advised regarding concomitant administration of clarithromycin with other ototoxic drugs, especially with aminoglycosides. Monitoring of vestibular and auditory function should be carried out during and after treatment.

Due to the risk for QT prolongation, clarithromycin should be used with caution in patients with coronary artery disease, severe cardiac insufficiency, hypomagnesemia, bradycardia (< 50 bpm), or when co-administered with other medicinal products associated with QT prolongation (see INTERACTIONS WITH OTHER MEDICINES). Clarithromycin must not be used in patients with congenital or documented acquired QT prolongation or history of ventricular arrhythmia (see CONTRAINDICATIONS).

Prophylaxis of Mycobacterium avium complex infection:
The majority of cases of disseminated *Mycobacterium avium* complex infection occur in patients with CD4 cell counts below 50 cells/mm³. Some authorities recommend delay of initiation of prophylaxis until the cell count has fallen to 50 cells/mm³.

Patients with duodenal ulcers
Patients with bleeding duodenal ulcers should be maintained on anti-secretory therapy.

Use in the elderly
Dosage adjustments are recommended in those patients with possible severe renal impairment (see DOSAGE AND ADMINISTRATION, PRECAUTIONS).

Carcinogenicity/mutagenicity
Clarithromycin gave negative results in a battery of mutagenicity studies with the exception of a positive result in an *in vitro* chromosome aberration assay. Long term studies in animals have not been performed to assess carcinogenic potential.

Use in pregnancy: Category B3
Clarithromycin should not be used in pregnant women except in clinical circumstances where no alternative therapy is appropriate. If pregnancy occurs while taking this drug, the patient should be apprised of the potential hazard to the foetus. Clarithromycin has demonstrated adverse effects on pregnancy outcome and/or embryo-foetal development in monkeys, rats, mice and rabbits at doses that produced plasma levels 2 to 17 times the serum levels achieved in humans treated at the maximum recommended doses.

Four teratogenicity studies in rats (3 with oral doses and one with intravenous doses up to 160 mg/kg/day administered during the period of organogenesis) and two in rabbits (at oral doses up to 125 mg/kg/day or intravenous doses of 160 mg/kg/day administered during gestation days 6 to 18) failed to demonstrate any teratogenicity due to clarithromycin. Two other studies in rats under similar conditions demonstrated a low incidence of cardiovascular anomalies at doses of 150 mg/kg/day administered during gestation days 6 to 15. Plasma AUC values after administration of 150 mg/kg/day to rats were approximately comparable with AUC values in
humans given 500 mg clarithromycin twice daily. Four studies in mice revealed a variable incidence of cleft palate following oral doses of 1000 mg/kg/day during gestation days 6 to 15. Cleft palate was also seen at 500 mg/kg/day. The 1000 mg/kg/day dose in mice resulted in AUC values 9 times the AUC values in humans given 500 mg clarithromycin twice a day. Abortions were observed in monkeys receiving 150 mg/kg/day on days 20 to 50 of pregnancy. AUC values in monkeys receiving this dose were about 2.5 fold higher than AUC values in humans given 500 mg clarithromycin twice daily.

Australian categorisation definition of:

**Category B3**
Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of foetal damage, the significance of which is considered uncertain in humans.

The safety of clarithromycin for use in pregnancy has not yet been established. Therefore, use during pregnancy is not advised without carefully weighing the benefits against risk.

**Use in lactation**
Clarithromycin and other macrolides are excreted in human breast milk. The safety of clarithromycin for use during breastfeeding of infants has not been established.

**Pneumonia**
In view of the emerging resistance of *Streptococcus pneumoniae* to macrolides, it is important that sensitivity testing be performed when prescribing clarithromycin for community-acquired pneumonia. In hospital-acquired pneumonia, clarithromycin should be used in combination with additional appropriate antibiotics.

**Skin and soft tissue infections of mild to moderate severity**
These infections are most often caused by *Staphylococcus aureus* and *Streptococcus pyogenes*, both of which may be resistant to macrolides. Therefore, it is important that sensitivity testing be performed. In cases where beta-lactam antibiotics cannot be used (e.g. allergy), other antibiotics, such as clindamycin, may be the drug of first choice. Currently, macrolides are only considered to play a role in some skin and soft tissue infections, such as those caused by *Corynebacterium minutissimum* (erythrasma), acne vulgaris, and erysipelas and in situations where penicillin treatment cannot be used.

In the event of severe acute hypersensitivity reactions, such as anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and Henoch-Schonlein purpura, clarithromycin therapy should be discontinued immediately and appropriate treatment should be urgently initiated.
Clarithromycin should be used with caution when administered concurrently with medications that induce the cytochrome CYP3A4 enzyme (see INTERACTIONS WITH OTHER MEDICINES).

Attention should also be paid to the possibility of cross resistance between clarithromycin and other macrolide drugs, as well as lincomycin and clindamycin.

**HMG-CoA reductase inhibitors (statins)**

Concomitant use of clarithromycin with lovastatin or simvastatin is contraindicated and treatment with these agents should be discontinued during treatment (see CONTRAINDICATIONS). As with other macrolides, clarithromycin has been reported to increase concentrations of HMG-CoA reductase inhibitors (see INTERACTIONS WITH OTHER MEDICINES). Rare reports of rhabdomyolysis have been reported in patients taking these drugs concomitantly. Patients should be monitored for signs and symptoms of myopathy. Rare reports of rhabdomyolysis have also been reported in patients taking atorvastatin or rosuvastatin concomitantly with clarithromycin. When used with clarithromycin, atorvastatin or rosuvastatin should be administered in the lowest possible doses. Adjustment of the statin dose or use of a statin that is not dependent on CYP3A metabolism (e.g. fluvastatin or pravastatin) should be considered.

**Oral hypoglycemic agents/Insulin**

The concomitant use of clarithromycin and oral hypoglycemic agents and/or insulin can result in significant hypoglycemia. With certain hypoglycemic drugs such as nateglinide, pioglitazone, repaglinide and rosiglitazone, inhibition of CYP3A enzyme by clarithromycin may be involved and could cause hypoglycemia when used concomitantly. Careful monitoring of glucose is recommended.

**Oral anticoagulants**

There is a risk of serious hemorrhage and significant elevations in International Normalized Ratio (INR) and prothrombin time when clarithromycin is co-administered with warfarin (see INTERACTIONS WITH OTHER MEDICINES). INR and prothrombin times should be frequently monitored while patients are receiving clarithromycin and oral anticoagulants concurrently.

**Effects on ability to drive and use machines**

There are no data on the effect of clarithromycin on the ability to drive or use machines. The potential for dizziness, vertigo, confusion and disorientation, which may occur with the medication, should be taken into account before patients drive or use machines.
INTERACTIONS WITH OTHER MEDICINES

The use of the following drugs is strictly contraindicated due to the potential for severe drug interaction effects

Cisapride, Pimozide

Elevated cisapride levels have been reported in patients receiving clarithromycin and cisapride concomitantly. This may result in QT prolongation and cardiac arrhythmias including ventricular tachycardia, ventricular fibrillation and torsade de pointes. Similar effects have been observed in patients taking clarithromycin and pimozide concomitantly (see CONTRAINDICATIONS).

Macrolides have been reported to alter the metabolism of terfenadine resulting in increased levels of terfenadine which has occasionally been associated with cardiac arrhythmias such as QT prolongation, ventricular tachycardia, ventricular fibrillation and torsades de pointes (see CONTRAINDICATIONS).

Ergotamine/dihydroergotamine

Postmarketing reports indicate that coadministration of clarithromycin with ergotamine or dihydroergotamine has been associated with acute ergot toxicity characterised by vasospasm and ischaemia of the extremities and other tissues, including the central nervous system. Hence, concomitant use of these medications is contraindicated.

Oral Midazolam

When midazolam was co-administered with clarithromycin tablets (500 mg twice daily), midazolam AUC was increased 7-fold after oral administration of midazolam. Concomitant administration of oral midazolam and clarithromycin is contraindicated.

Effects of Other medical products on Clarithromycin

Drugs that are inducers of CYP3A (e.g. rifampicin, phenytoin, carbamazepine, phenobarbital, St John’s wort) may induce the metabolism of clarithromycin. This may result in sub-therapeutic levels of clarithromycin leading to reduced efficacy. Furthermore, it might be necessary to monitor the plasma levels of the CYP3A inducer, which could be increased owing to the inhibition of CYP3A by clarithromycin (see also the relevant product information for the CYP3A4 inducer administered). Concomitant administration of rifabutin and clarithromycin resulted in an increase in rifabutin, and decrease in clarithromycin serum levels together with an increased risk of uveitis.

The following drugs are known or suspected to affect circulating concentrations of clarithromycin; clarithromycin dosage adjustment or consideration of alternative treatments may be required.
Efavirenz, nevirapine, rifampicin, and rifabutin

Strong inducers of the cytochrome P450 metabolism system such as efavirenz, nevirapine, rifampicin, and rifabutin may accelerate the metabolism of clarithromycin and thus lower the plasma levels of clarithromycin, while increasing those of 14-OH-clarithromycin, a metabolite that is also microbiologically active. Since the microbiological activities of clarithromycin and 14-OH-clarithromycin are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of clarithromycin and enzyme inducers.

Etravirine

Clarithromycin exposure was decreased by etravirine; however, concentrations of the active metabolite, 14-OH-clarithromycin, were increased. Because 14-OH-clarithromycin has reduced activity against Mycobacterium avium complex (MAC), overall activity against this pathogen may be altered; therefore alternatives to clarithromycin should be considered for the treatment of MAC.

Fluconazole

Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy adult volunteers led to increases in the mean steady-state of clarithromycin $C_{\text{min}}$ and AUC of 33% and 18%, respectively. Steady-state concentrations of 14-OH-clarithromycin were not significantly affected by concomitant administration of fluconazole. No clarithromycin dose adjustment is necessary.

Ritonavir

A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200 mg every eight hours and clarithromycin 500 mg every 12 hours resulted in a marked inhibition of the metabolism of clarithromycin. The clarithromycin $C_{\text{max}}$ increased by 31%, $C_{\text{min}}$ increased 182% and AUC increased by 77% with concomitant administration of ritonavir. An essentially complete inhibition (99.8% decrease) of the formation of 14-OH-clarithromycin was noted. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function. However, for patients with renal impairment, the following dosage adjustments should be considered: For patients with $CL_{\text{CR}}$ 30 to 60 mL/min the dose of clarithromycin should be reduced by 50%. For patients with $CL_{\text{CR}} < 30$ mL/min the dose of clarithromycin should be decreased by 75%. Doses of clarithromycin greater than 1 g/day should not be coadministered with ritonavir.

Similar dose adjustments should be considered in patients with reduced renal function when ritonavir is used as a pharmacokinetic enhancer with other HIV protease inhibitors including atazanavir and saquinavir (see section below, Bi-Directional Drug Interactions).
Conversely, clarithromycin increases ritonavir AUC by 12%; no dosage adjustment of ritonavir is recommended.

Theoretical potential interactions

Fluoxetine is partially metabolised by the 2D6 isoform of P450. It is a weak inhibitor of CYP3A; theoretically, this inhibition could result in possible elevation of clarithromycin levels.

Effects of Clarithromycin on Other Drugs

CYP3A-based interactions

Co-administration of clarithromycin, known to inhibit CYP3A, and a drug primarily metabolised by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug. Clarithromycin should be used with caution in patients receiving treatment with other drugs known to be CYP3A enzyme substrates, especially if the CYP3A substrate has a narrow safety margin (e.g. carbamazepine) and/or the substrate is extensively metabolized by this enzyme.

Dosage adjustments may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin.

Theophylline, carbamazepine

Results of clinical studies indicate there was a modest but statistically significant (p ≤ 0.05) increase of circulating theophylline or carbamazepine levels when either of these drugs were administered concomitantly with clarithromycin. Dose reduction may need to be considered.

Theophylline

Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations. Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range. In two studies in which theophylline was administered with clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 mg or 500 mg q 12 h clarithromycin), the steady-state levels of $C_{\text{max}}$, $C_{\text{min}}$, and the area under the serum concentration time curve (AUC) increased about 20%. Theophylline dosage may need to be reduced.

Carbamazepine

Single-dose administration of clarithromycin has been shown to result in increased concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered.
Zidovudine

Simultaneous oral administration of clarithromycin and zidovudine in HIV infected adult patients may result in decreased steady-state zidovudine concentrations. Because clarithromycin appears to interfere with the absorption of simultaneously administered oral zidovudine, this interaction can largely be avoided by staggering the doses of clarithromycin and zidovudine by at least two hours. This interaction does not appear to occur in paediatric HIV infected patients taking clarithromycin suspensions with zidovudine or didanosine.

Cytochrome P450 Effects

Clarithromycin may enhance and/or prolong the hypoglycaemic effect of repaglinide. In an interaction study in healthy volunteers, co-administration of 250mg clarithromycin, a mechanism based inhibitor of CYP3A4, increased the repaglinide AUC by 40% and C_{max} by 67%, and increased the mean incremental AUC of serum insulin by 51% and the maximum concentration by 61%. The exact mechanism of this interaction is not clear.

Cytochrome P450 3A (CYP3A)

Cytochrome P450 3A (CYP3A) is the major isoform involved in clarithromycin metabolism. As with other macrolide antibiotics, the use of clarithromycin in patients concurrently taking drugs metabolised by the cytochrome P450 system (e.g. alprazolam, cilostazol, oral anticoagulants such as warfarin, atypical antipsychotics (e.g. quetiapine), ergot alkaloids, lovastatin, methylprednisolone, omeprazole, quinidine, simvastatin, terfenadine, theophylline, triazolam, valproate, vinblastine, midazolam, disopyramide, phenytoin, digoxin, tacrolimis, cyclosporin rifabutin and sildenafil) may be associated with elevations in serum levels of these other drugs.

The following CYP3A based drug interactions have been observed with erythromycin products and/or with clarithromycin in postmarketing experience:

Antiarrhythmics

There have been postmarketing reports of torsades de pointes occurring with concurrent use of clarithromycin and quinidine or disopyramide. Electrocardiograms should be monitored for QT prolongation during co-administration of clarithromycin with these drugs. Serum levels of quinidine and disopyramide should be monitored during clarithromycin therapy.

There have been post marketing reports of hypoglycaemia with the concomitant administration of clarithromycin and disopyramide. Therefore blood glucose levels should be monitored during concomitant administration of clarithromycin and disopyramide.
**Omeprazole**

Clarithromycin (500mg every 8 hours) was given in combination with omeprazole (40mg daily) to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased ($C_{\text{max}}$, $AUC_{0-24}$ and $T_{1/2}$ increased by 30%, 89% and 34% respectively), by the concomitant administration of clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when omeprazole was co-administered with clarithromycin.

**Sildenafil, tadalafil, and vardenafil**

Each of these phosphodiesterase inhibitors is metabolised, at least in part, by CYP3A, and CYP3A may be inhibited by concomitantly administered clarithromycin. Co-administration of clarithromycin with sildenafil, tadalafil or vardenafil would likely result in increased phosphodiesterase inhibitor exposure. Reduction of sildenafil, tadalafil and vardenafil dosages should be considered when these drugs are co-administered with clarithromycin.

**Tolterodine**

The primary route of metabolism for tolterodine is via the 2D6 isoform of cytochrome P450 (CYP2D6). However, in a subset of the population devoid of CYP2D6, the identified pathway of metabolism is via CYP3A. In this population subset, inhibition of CYP3A results in significantly higher serum concentrations of tolterodine. A reduction in tolterodine dosage may be necessary in the presence of CYP3A inhibitors, such as clarithromycin in the CYP2D6 poor metabolizer population.

**Repaglinide**

Clarithromycin may enhance and/or prolong the hypoglycaemic effect of repaglinide. In an interaction study in healthy volunteers, co-administration of 250 mg clarithromycin, a mechanism based inhibitor of CYP3A4, increased the repaglinide AUC by 40% and $C_{\text{max}}$ by 67%, and increased the mean incremental AUC of serum insulin by 51% and the maximum concentration by 61%. The exact mechanism of this interaction is not clear.

**Triazolobenzodiazepine: (such as triazolamand alprazolam) and related benzodiazepines (such as midazolam)**

Erythromycin has been reported to decrease the clearance of triazolam and midazolam, and thus, may increase the pharmacological effect of these benzodiazepines. Concomitant administration of oral midazolam and clarithromycin is contraindicated. If intravenous midazolam is co-administered with clarithromycin, the patient must be closely monitored to allow dose adjustment.
The same precautions should also apply to other benzodiazepines that are metabolised by CYP3A, including triazolam and alprazolam. For benzodiazepines, which are not dependent on CYP3A for their elimination (temazepam, nitrazepam, lorazepam), a clinically important interaction with clarithromycin is unlikely.

There have been post-marketing reports of drug interactions and CNS effects (e.g., somnolence and confusion) with the concomitant clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested.

There have also been reports of clarithromycin interactions with carbamazepine, cyclosporin, phenytoin, and tacrolimus:

- Carbamazepine, cyclosporin, and tacrolimus are metabolised by CYP3A.
- Phenytoin is metabolised by the P450 system, although not by the 3A isoform.

Rhabdomyolysis coincident with the co-administration of clarithromycin and the HMG-CoA reductase inhibitors, lovastatin and simvastatin, has been rarely reported.

**Other Drug Interactions**

**Aminoglycosides**

Caution is advised regarding concomitant administration of clarithromycin with other ototoxic drugs, especially with aminoglycosides (see PRECAUTIONS).

**Colchicine**

Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When clarithromycin and colchicine are administered together, inhibition of Pgp and/or CYP3A by clarithromycin may lead to increased exposure to colchicine. Concomitant use of clarithromycin and colchicine is contraindicated (see CONTRAINDICATIONS and PRECAUTIONS).

**Digoxin**

Digoxin is thought to be a substrate for the efflux transporter, P-glycoprotein (Pgp). Clarithromycin is known to inhibit Pgp. When clarithromycin and digoxin are administered together, inhibition of Pgp by clarithromycin may lead to increased exposure to digoxin. Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have also been reported in post marketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Serum digoxin concentrations should be carefully monitored while patients are receiving digoxin and clarithromycin simultaneously.
Phenytoin and valproate

There have been spontaneous or published reports of interactions of CYP3A inhibitors, including clarithromycin with drugs not thought to be metabolised by CYP3A (e.g. phenytoin and valproate). Serum level determinations are recommended for these drugs when administered concomitantly with clarithromycin. Increased serum levels have been reported.

Bi-Directional Drug Interactions

Atazanavir

Both clarithromycin and atazanavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. Because of the large therapeutic window for clarithromycin, no dosage reduction should be necessary in patients with normal renal function. For patients with moderate renal function (creatinine clearance 30 to 60 mL/min), the dose of clarithromycin should be decreased by 50%. For patients with creatinine clearance <30mL/min, the dose of clarithromycin should be decreased by 75% using an appropriate clarithromycin formulation. Doses of clarithromycin greater than 1000 mg per day should not be co-administered with protease inhibitors.

Itraconazole

Both clarithromycin and itraconazole are substrates and inhibitors of CYP3A, leading to a bi-directional drug interaction. Clarithromycin may increase the plasma levels of itraconazole, while itraconazole may increase the plasma levels of clarithromycin. Patients taking itraconazole and clarithromycin concomitantly should be monitored closely for signs or symptoms of increased or prolonged pharmacologic effect.

Saquinavir

Both clarithromycin and saquinavir are substrates and inhibitors of CYP3A, and there is evidence of a bi-directional drug interaction. When saquinavir is co-administered with ritonavir, consideration should be given to the potential effects of ritonavir on clarithromycin (see PRECAUTIONS, INTERACTIONS WITH OTHER MEDICINES).

Calcium Channel Blockers

Acute kidney injury has been reported in patients using clarithromycin and calcium channel blockers (CCBs) metabolised by CYP3A4 (e.g. verapamil, amlodipine, diltiazem), although the causal association cannot be established. Most of these cases involved elderly patients 65 years of age or older.

Caution is advised regarding the concomitant administration of clarithromycin and calcium channel blockers metabolised by CYP3A4 (e.g., verapamil, amlodipine, diltiazem) due to the risk of hypotension. Plasma concentrations of clarithromycin as well as calcium channel blockers
may increase due to the interaction. Hypotension, bradyarrhythmias and lactic acidosis have been observed in patients taking clarithromycin and verapamil concomitantly.

**Interaction that has been investigated, for which outcome was negative**

**Didanosine**

Simultaneous administration of clarithromycin tablets and didanosine in 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.

**Indinavir**

The potential pharmacokinetic interaction between indinavir and clarithromycin was assessed in a 3-period, randomised, crossover, multiple-dose study. Plasma concentration profiles of indinavir were consistently slightly higher in the presence of clarithromycin, although $C_{\text{max}}$ changed minimally. Thus, clarithromycin has a modest inhibitory effect on indinavir metabolism. Results suggest that indinavir competitively inhibits the oxidative metabolism of clarithromycin. The magnitude of the changes in the pharmacokinetics of clarithromycin and indinavir were not considered to be clinically significant, and co-administration of the drugs does not require dose-adjustment.

**Ketoconazole**

Ketoconazole appreciably inhibits the N-demethylation of erythromycin (86%). At this time there is no data regarding concomitant administration of ketoconazole and clarithromycin.

**ADVERSE EFFECTS**

**Clinical Trial Experience**

**Non Mycobacterial Infections:** At the recommended doses for non-mycobacterial infections, clarithromycin was generally well tolerated in the reported clinical trials. The incidence of adverse reactions considered to be remotely, possibly or probably related to treatment was comparable in nature to that with other macrolide antibiotics. Most reactions were described as mild to moderately severe; less than 1% were described as severe. Fewer than 3% of patients discontinued therapy because of drug related side effects. The following side effects have been reported as common (1-10%) and uncommon (0.1-1%).
<table>
<thead>
<tr>
<th>Body System</th>
<th>Clarithromycin 250mg Tablets</th>
<th>Clarithromycin 500mg Tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>N=4532</td>
<td>N=658</td>
</tr>
<tr>
<td>Body as a Whole</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>infection, asthenia</td>
<td>fever</td>
</tr>
<tr>
<td>Uncommon</td>
<td>body aches and pains</td>
<td></td>
</tr>
<tr>
<td>Cardiovascular System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>chest pain</td>
<td></td>
</tr>
<tr>
<td>Central Nervous System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>headache*, dizziness</td>
<td>headache</td>
</tr>
<tr>
<td>Uncommon</td>
<td>depression, sleep disturbance,</td>
<td></td>
</tr>
<tr>
<td></td>
<td>tremor, flushing</td>
<td></td>
</tr>
<tr>
<td>Eye Disorders</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uncommon</td>
<td>photophobia</td>
<td></td>
</tr>
<tr>
<td>Digestive System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>nausea*, vomiting*, abdominal</td>
<td>nausea*, vomiting*,</td>
</tr>
<tr>
<td></td>
<td>pain*, diarrhoea*, constipation*</td>
<td>abdominal pain*,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>diarrhoea*,</td>
</tr>
<tr>
<td>Uncommon</td>
<td>bleeding gums, heartburn,</td>
<td>flatulence*,</td>
</tr>
<tr>
<td></td>
<td>stomatitis, blood stained stools</td>
<td>dyspepsia</td>
</tr>
<tr>
<td>Haematopoietic &amp; Lymphatic System</td>
<td>Uncommon</td>
<td>increased prothrombin time</td>
</tr>
<tr>
<td>Metabolic &amp; Nutritional</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common</td>
<td>increases in ALT, AST*</td>
<td>increases in ALTL,AST*,</td>
</tr>
<tr>
<td></td>
<td></td>
<td>alkaline phosphatase</td>
</tr>
<tr>
<td>Uncommon</td>
<td>increases in LDH, alkaline phosphatase, bilirubin, urea nitrogen*</td>
<td></td>
</tr>
<tr>
<td>Musculoskeletal</td>
<td>Uncommon</td>
<td>backpain</td>
</tr>
<tr>
<td>Respiratory System</td>
<td>Common</td>
<td>dyspnoea*</td>
</tr>
</tbody>
</table>
Skin and Skin Structure

<table>
<thead>
<tr>
<th>Common</th>
<th>pruritis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uncommon</td>
<td>pustular rash (non urticarial)</td>
</tr>
<tr>
<td></td>
<td>stained finger nails</td>
</tr>
</tbody>
</table>

Special Senses

<table>
<thead>
<tr>
<th>Uncommon</th>
<th>taste perversion</th>
</tr>
</thead>
</table>

* See Immunocompromised and HIV/AIDS patients

**Hepatic System:** As with other macrolides, hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with and without jaundice, has been infrequently reported with clarithromycin. This hepatic dysfunction may be severe and is usually reversible. In very rare instances (0.03%), hepatic failure with fatal outcomes has been reported and generally has been associated with serious underlying diseases and/or concomitant medications.

The following adverse events have not been reported in clinical trials with clarithromycin but have rarely been associated with erythromycin products - ventricular arrhythmias, including ventricular tachycardia and torsades de pointes in individuals with prolonged QT intervals.

**Immunocompromised and HIV/AIDS Patients:** In AIDS and other immunocompromised patients treated with the higher doses of clarithromycin over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse events possibly associated with clarithromycin administration from underlying signs of HIV disease or intercurrent illness.

In adult patients, the most frequently reported adverse drug events by patients treated with total daily doses of 1000 mg - 2000 mg of clarithromycin are: are reported in the table above. The incidence is generally 3 - 4 times more frequent for those patients treated with total daily doses of 4000 mg of clarithromycin.

On the basis of these criteria, about 2% to 3% of these patients who received 1000 mg or 2000 mg of clarithromycin daily had seriously abnormal elevated levels (greater than three times upper limit of normal) of aspartate transaminase (AST) and alanine transaminase (ALT) and abnormally low white blood cell (less than 2 x 10^9/L) or platelet (less than 75 x 10^9/L) counts. A lower percentage of patients in these two dosage groups also had elevated blood urea nitrogen levels. Slightly higher incidences of abnormal laboratory values were also noted with these patients for all parameters except for white blood cell count (WBC).

**Elderly Patients:** Limited data is available in elderly patients with Mycobacterium avium complex infections. In a clinical study, 11/13 patients on doses of clarithromycin between 1000 mg and 2000 mg per day discontinued therapy due to adverse events.
Other Reported Side Effects: In addition to hepatic dysfunction, side effects such as pseudomembranous colitis, pancreatitis, thrombocytopenia, and a reduction in prothrombin time have also been reported with the use of clarithromycin.

Post-Marketing Experience:

Additional adverse reactions reported spontaneously since the Clarithromycin tablet formulation was marketed are as follows:

Body as a Whole:
Very rare (<0.01%): Anaphylaxis, abdominal pain, asthenia, allergic reaction, fever, headache, angioedema.

Skin and Skin Structure:
Very rare (<0.01%): Steven-Johnson Syndrome, urticaria, rash, hyperhidrosis, pruritis, toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms (DRESS), acne, Henoch-Schonlein purpura.

Central Nervous System:
Very rare (<0.01%): Anxiety, insomnia*, hallucinations, confusion, psychosis, vertigo, dizziness, dream abnormality, tinnitus, disorientation, depersonalisation, confusion, nervousness, hyperkinesias, depression, paraesthesia, mania. There have been rare reports of convulsions.

Haematopoietic & Lymphatic System:
Very rare (<0.01%): Decreased white blood cell counts, decreased platelet counts, thrombocytopenia, leucopenia, agranulocytosis.

Metabolic & Nutritional:
Very rare (<0.01%): Increased serum creatinine, increased gamma glutaryl transferase (GGT), hypoglycaemia.

Special Senses:
Very rare (<0.01%): Hearing disturbances, dysgeusia, taste perversion, smell perversion, ageusia, anosmia otitis media.

Digestive System:
Very rare (<0.01%): Dry mouth, tongue discolouration, glossitis, moniliasis oral, stomatitis, diarrhoea, nausea, vomiting, liver abnormalities, tooth discolouration, dyspepsia, enteritis. There have been rare reports of pancreatitis.

Respiratory System:
Very rare (<0.01%): Dyspnoea

Urogenital System:
Very rare (<0.01%): Isolated cases of increased serum creatinine have been reported but an
association has not been established. There have been reports of interstitial nephritis coincident with clarithromycin use. Dysuria, renal failure.

Cardiac System:
Torsade de pointes, electrocardiogram QT prolonged, ventricular tachycardia, ventricular fibrillation.

Hepatobiliary system:
Very rare (<0.01%) Hepatic failure, hepatitis, cholestatic hepatitis, cholestatic jaundice, hepatocellular jaundice, abnormal hepatic function.

Musculoskeletal and Connective Tissue Disorders:
Very rare (<0.01%) Myalgia, rhabdomyolysis, myopathy.

Infections and Infestations:
Pseudomembranous colitis, erysipelas, erythrasma.

Vascular Disorders:
Haemorrhage.

Investigations:
International Normalised Ratio (INR) increased, prothrombin time prolonged, urine colour abnormal.

Description of selected adverse effects

In very rare instances, hepatic failure with fatal outcome has been reported and generally has been associated with serious underlying diseases and/or concomitant medications (see PRECAUTIONS).

A special attention to diarrhea should be paid as Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents including clarithromycin, and may range in severity from mild diarrhea to fatal colitis (see PRECAUTIONS).

As with other macrolides, QT prolongation, ventricular tachycardia, and torsade de pointes have rarely been reported with clarithromycin (see PRECAUTIONS AND INTERACTIONS WITH OTHER MEDICINES).

Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clarithromycin, and may range in severity from mild to life threatening (see PRECAUTIONS).

In some of the reports of rhabdomyolysis, clarithromycin was administered concomitantly with statins, fibrates, colchicine or allopurinol (see CONTRAINDICATIONS, PRECAUTIONS).
There have been post-marketing reports of colchicine toxicity with concomitant use of clarithromycin and colchicine, especially in elderly and/or patients with renal insufficiency, some with a fatal outcome (see PRECAUTIONS, INTERACTIONS WITH OTHER MEDICINES).

There have been rare reports of hypoglycemia, some of which have occurred in patients on concomitant oral hypoglycemic agents or insulin (see PRECAUTIONS, INTERACTIONS WITH OTHER MEDICINES).

There have been post-marketing reports of drug interactions and central nervous system (CNS) effects (e.g. somnolence and confusion) with the concomitant use of clarithromycin and triazolam. Monitoring the patient for increased CNS pharmacological effects is suggested (see INTERACTIONS WITH OTHER MEDICINES).

There is a risk of serious hemorrhage and significant elevations in INR and prothrombin time when clarithromycin is co-administered with warfarin. (see PRECAUTIONS, INTERACTIONS WITH OTHER MEDICINES).

**DOSAGE AND ADMINISTRATION**

**Adults**

*Patients with nonmycobacterial infections:* The usual recommended dosage of clarithromycin is 250 mg twice daily. In more severe infections, the dosage can be increased to 500 mg twice daily. The usual duration of therapy is 7 to 14 days.

For the treatment of *Legionella pneumophila* infection, a dose of 500 mg twice daily for 4 weeks is appropriate.

In patients with renal impairment with creatinine clearance less than 30 mL/min, the dosage of clarithromycin should be reduced by one-half, ie 250 mg once daily, or 250 mg twice daily in more severe infections. Dosage should not be continued beyond 14 days in these patients.

**NOTE:** In the treatment of haemolytic streptococcal infections, a therapeutic regimen should be administered for at least 10 days.

*Patients with peptic ulcers:* For the eradication of *H. pylori*, the recommended dosage regimen is clarithromycin 500 mg bid in conjunction with amoxycillin 1000 mg bid and omeprazole 20 mg twice daily for 7 - 10 days.

Patients should be retreated if there is a return of symptoms and *H. pylori* infection. However, in this situation, possible resistance of the organism to the antimicrobial agents should be considered.
The optimal treatment regimen for the eradication of *H. pylori* is yet to be determined.

**Patients with mycobacterial infections**

**A. Treatment of mycobacterial infections:**

**Use in adults:**
The recommended dosage for adults and children older than 12 years with disseminated or localised mycobacterial infections is 500 mg twice daily. This may be increased to 1000 mg twice daily if no clinical or bacteriological response is seen after 3-4 weeks of therapy.

**Use in children:**
The recommended dosage for children (< 12 years) with disseminated or local mycobacterial infections is 15 - 30 mg/kg per day in 2 divided doses.

**Use in the elderly:**
Experience in patients older than 65 years is limited. The recommended starting dose for elderly patients with calculated creatinine clearance of greater than 30 mL/min is 500 mg twice a day. A further reduction of the initial dose and dose titration is recommended in those patients with possible severe renal impairment. (see PRECAUTIONS, ADVERSE EFFECTS)

Clarithromycin should be used in conjunction with other antimycobacterial agents; the optimal regimen for treating patients with mycobacterial infections is yet to be determined.

Treatment with clarithromycin should continue as long as clinical benefit is demonstrated.

**B. Prophylaxis of mycobacterial infections:**

**Use in adults:**
The recommended dosage of clarithromycin in HIV-infected adults with CD4 lymphocyte counts <75 cells/mm³ for prophylaxis of disseminated *Mycobacterium avium* complex infections is 500 mg twice daily. Disseminated disease due to *Mycobacterium avium* complex should be excluded by a negative blood culture prior to commencement of prophylaxis, and concurrent medication reviewed to avoid the possibility of drug interaction. Should prophylaxis fail, at least two other nonmacrolide agents with good antimycobacterial activity should be chosen empirically, as the isolate of *Mycobacterium avium* complex may be highly resistant to clarithromycin and other macrolides.

Clarithromycin has not been studied as a prophylactic agent in mycobacterial infections in other immunocompromised groups or in HIV-infected children. Also, clarithromycin has no useful activity against *Mycobacterium tuberculosis*.
OVERDOSAGE

Contact the Poisons Information Centre on 13 11 26 for advice on management of overdose.

Symptoms:
Reports indicate that the ingestion of large amounts of clarithromycin can be expected to produce pronounced gastrointestinal symptoms. Severe liver toxicity, including cholestatic jaundice may occur.

Treatment:
There is no known antidote. General supportive measures and the use of activated charcoal (where physicochemically appropriate) have generally been seen as acceptable recommendations. As with other macrolides, clarithromycin serum levels are not expected to be appreciably affected by haemodialysis or peritoneal dialysis.

PRESENTATION AND STORAGE CONDITIONS

Clarithromycin Sandoz 250mg is a white, oblong, convex, coated tablet scored on both faces and contains 250mg clarithromycin. Available in blister packs (PVC/Al) of 14 and 100* tablets.

Clarithromycin Sandoz 500mg* is a white, oblong, convex, coated tablet scored on both faces and contains 500mg clarithromycin. Available in blister packs (PVC/Al) of 42* and 100* tablets.

*Not currently marketed in Australia

Store below 25°C.

NAME AND ADDRESS OF THE SPONSOR

Sandoz Pty Ltd
ABN 60 075 449 553
54 Waterloo Road
Macquarie Park
NSW 2113
Australia
Tel: 1800 634 500

POISON SCHEDULE OF THE MEDICINE

Schedule 4 – Prescription Only Medicine

Date of first inclusion in the Australian Register of Therapeutic Goods (the ARTG): 29/08/2005

Date of most recent amendment: 18/07/2016